Related Experiment Video
Updated: Jan 13, 2026

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
A Newly Discovered Obolenskvirus Phage with Sustained Lytic Activity Against Multidrug-Resistant Acinetobacter
Eduardo Vera-Jauregui1, María Guadalupe Avila-Novoa1, Berenice González-Torres2
1Centro de Investigación en Biotecnología Microbiana y Alimentaria, Departamento de Ciencias Básicas, División de Desarrollo Biotecnológico, Centro Universitario de la Ciénega, Universidad de Guadalajara, Av. Universidad 1115, Col. Lindavista, Ocotlan 47820, Mexico.
Abstract:
Background: Acinetobacter baumannii is a highly concerning pathogen in hospital settings, responsible for severe infections such as ventilator-associated pneumonia, urinary tract infections, and meningitis. Its remarkable genetic plasticity facilitates the rapid acquisition of antibiotic resistance, significantly complicating treatment and increasing mortality rates. As multidrug-resistant (MDR) infections continue to rise, phage therapy emerges as a viable alternative. Methods: This study reports the isolation and characterization of Acinetobacter phage vB_AbaM_A72 from stagnant water in Jalisco, Mexico. Results: Transmission electron microscopy revealed a myovirus-like morphology with an icosahedral head (91.32 ± 0.12 nm) and a contractile tail (123.77 ± 0.19 nm). The phage exhibited high environmental resilience, tolerating temperatures up to 60 °C and pH ranging from 5 to 11. Notably, A72 demonstrated a narrow host range but effectively inhibited the growth of an MDR A. baumannii strain for at least 12 h across different multiplicities of infection. Whole-genome sequencing confirmed the absence of virulence, antibiotic resistance, or lysogeny-associated genes. Comparative genomic analysis identified A72 as the first member of a newly described Obolenskvirus species, sharing only 76.4% similarity with its closest relatives. Conclusions: These findings underscore the importance of fully characterizing novel bacteriophages to expand therapeutic libraries and reinforce the feasibility of phage therapy as a promising approach against MDR A. baumannii infections.
Insights
A novel bacteriophage, A72, effectively targets multidrug-resistant Acinetobacter baumannii. This discovery supports phage therapy as a promising treatment against challenging bacterial infections.
Area of Science:
- Microbiology
- Virology
- Genomics
Background:
- Acinetobacter baumannii is a critical hospital-acquired pathogen.
- Rapid antibiotic resistance in A. baumannii complicates treatment.
- Phage therapy offers a potential alternative to antibiotics.
Purpose of the Study:
- To isolate and characterize a novel bacteriophage against multidrug-resistant A. baumannii.
- To evaluate the therapeutic potential of the isolated phage.
Main Methods:
- Isolation and characterization of Acinetobacter phage vB_AbaM_A72.
- Transmission electron microscopy for morphology assessment.
- Whole-genome sequencing and comparative genomic analysis.
Main Results:
- Phage A72 exhibits myovirus-like morphology and high environmental resilience.
- A72 effectively inhibits multidrug-resistant A. baumannii growth for over 12 hours.
- Genomic analysis reveals no virulence or resistance genes, classifying A72 in a new Obolenskvirus species.
Conclusions:
- Characterizing novel bacteriophages is crucial for expanding therapeutic options.
- Phage therapy presents a viable strategy against multidrug-resistant A. baumannii infections.
Related Concept Videos
DNA Bacteriophages
Lytic Cycle of Bacteriophages
Viruses of Archaea
Viral Replication: Lytic Cycle
Viral Replication: Lysogenic Cycle
Lysogenic Cycle of Bacteriophages

